SCOPE
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
2.2.1. Primary & Secondary Sources
2.3. Market Breakdown & Data Triangulation
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary research respondent, By Region
2.5. Assumption & Limitation
3. Executive Summary
4. Global Vaccine market Industry Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraint
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape/Recent Development
4.4. Regulatory Framework
4.5. Company Market Share Analysis, 2019
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Suppliers
4.6.2. Bargaining Power of Buyers
4.6.3. Threat of New Entrants
4.6.4. Threat of Substitutes
4.6.5. Intensity of Rivalry
4.7. Impact of COVID 19
5. Global Vaccine market Overview
5.1. Market Size & Forecast by Value, 2016-2026
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Technology
5.2.1.1. Live
5.2.1.2. Toxoid
5.2.1.3. Recombinant
5.2.2. By Disease
5.2.2.1. Pneumococcal
5.2.2.2. Influenza
5.2.2.3. DTP
5.2.2.4. Rotavirus
5.2.2.5. TT
5.2.2.6. Polio
5.2.2.7. MMR
5.2.2.8. Varicella
5.2.2.9. Dengue
5.2.2.10. TB,
5.2.2.11. Shingles
5.2.2.12. Rabies
5.2.3. By Route
5.2.3.1. IM
5.2.3.2. SC
5.2.3.3. ID
5.2.3.4. Oral
5.2.4. By Patient
5.2.4.1. Pediatric
5.2.4.2. Adult
5.2.5. By Region
5.2.5.1. North America
5.2.5.2. Europe
5.2.5.3. Asia Pacific
5.2.5.4. Latin America
5.2.5.5. Middle East & Africa
6. North America Vaccine Market
6.1. Market Size & Forecast by Value, 2016-2026
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Disease
6.2.3. By Route
6.2.4. By Patient
6.2.5. By Country
6.2.5.1. United States
6.2.5.2. Canada
7. Europe Vaccine market
7.1. Market Size & Forecast by Value, 2016-2026
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Disease
7.2.3. By Route
7.2.4. By Patient
7.2.5. By Country
7.2.5.1. Germany
7.2.5.2. United Kingdom
7.2.5.3. France
7.2.5.4. Italy
7.2.5.5. Spain
7.2.5.6. Rest of Europe
8. Asia Pacific Vaccine Market
8.1. Market Size & Forecast by Value, 2016-2026
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Disease
8.2.3. By Route
8.2.4. By Patient
8.2.5. By Country
8.2.5.1. India
8.2.5.2. China
8.2.5.3. Japan
8.2.5.4. South Korea
8.2.5.5. Rest of Asia Pacific
9. Latin America Vaccine Market
9.1. Market Size & Forecast by Value, 2016-2026
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1.1. By Technology
9.2.1.2. By Disease
9.2.1.3. By Route
9.2.1.4. By Patient
9.2.1.5. By Country
9.2.1.5.1. Brazil
9.2.1.5.2. Mexico
9.2.1.5.3. Rest of Latin America
10.Middle East & Africa Vaccine Market
10.1. Market Size & Forecast by Value, 2016-2026
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1.1. By Technology
10.2.1.2. By Disease
10.2.1.3. By Route
10.2.1.4. By Patient
10.2.1.5. By Country
10.2.1.5.1. Saudi Arabia
10.2.1.5.2. UAE
10.2.1.5.3. South Africa
10.2.1.5.4. Rest of Middle East & Africa
11.Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
11.1. Glaxosmithkline PLC
11.2. Pfizer, Inc
11.3. Merck & Co., Inc
11.4. Sanofi Pasteur SA
11.5. CSL Limited
11.6. Emergent Biosolutions, Inc
11.7. Johnson & Johnson
11.8. Astrazeneca
11.9. Serum Institute of India Pvt., LTD
11.10. Bavarian Nordic
11.11. Mitsubishi Tanabe Pharma Corporation
11.12. Daiichi Sankyo Company, Limited
11.13. Panacea Biotec, LTD
11.14. Biological E
11.15. Bharat Biotech .
11.16. Other Prominent Players
* Financial details in case of unlisted companies will be available as per data availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.
